Lee Sang-heon, CEO of OSCOTECInc: "₩2.5B investment led to ₩1.5T L/O achievement, proven through new drug"
Predicted impact: Low
CEO interview recapping an earlier licensing deal; no new terms disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.